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28 Abstract 
29 
30 Aim 
31 To study the signature of 87 urinary miRNAs in Duchenne muscular dystrophy    (DMD) 
32 patients, select the most dysregulated and determine statistically significant differences   in 
33 their expression between controls, ambulant and non-ambulant DMD patients, and    patients 
34 on different corticosteroid  regimens. 
 
35 
36 Patients/materials  & methods 
37 Urine was collected from control (n =20), ambulant (n =31) and non-ambulant (n =23) DMD 
38 patients. MiRNA expression was measured by  RT-qPCR. 
39 
40 Results 
41 MiR-29c-3p was significantly downregulated in ambulant DMD patients while miR-23    -3p 
42 and miR-21-5p were significantly downregulated in non-ambulant DMD patients    compared 
43 to age matched controls. 
 
44 
45 Conclusions 
46 MiR-29c-3p, miR-23 -3p and miR-21-5p are promising novel non-invasive biomarkers    for 
47 DMD, and miR-29c-3p levels are differentially affected by different steroid   regimens, 
48 supporting the antifibrotic effect of steroid  therapy. 
49 
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52 
53 1. Introduction 
54 Duchenne   muscular   dystrophy   (DMD)   is   an   X-linked   and   progressive  neuromuscular 
55 disorder affecting 1 in 5000 newborn males [1]. It is more commonly caused by out-of-frame 
56 deletions  or,  more  rarely,  duplications,  nonsense  or  other  small  mutations  affecting      the 
57 dystrophin gene (DMD) [2]. DMD is the largest gene in the human genome. Its sequence, 
58 spanning ~2.3 megabases, [3] encodes dystrophin, a 427 kDa protein principally expressed in 
59 skeletal and cardiac muscle, connecting the sarcolemma to the actin cytoskeleton. Dystrophin 
60 plays  a  significant  structural  role  by  giving  plasticity  and  flexibility  to  the  muscle fibers, 
61 ensuring  stability  over  the  contraction-relaxation  phase  [4].  Affected  children  are typically 
62 diagnosed between 3 and 5 years of age and the progressive skeletal muscle weakness and 
63 wasting  used  to  lead  to  loss  of   ambulation  at  a  mean  age   of   9.5  years.   Due   to     the 
64 implementation of  current standards  of  care  and corticosteroid administration,  the  mean age 
65 at which ambulation is lost has shifted to 12-14 years  [5]. 
66 
67 Prednisolone  and  deflazacort are  the  most commonly used  corticosteroids,  administered  on 
68 either  a  daily or  intermittent  regimens  [6].  The  mechanism  underlying the pharmacological 
69 action of these corticosteroids is not completely understood, but is likely to involve both an 
70 anti-inflammatory  action  and  anabolic  effects  in  dystrophic  muscle  via  the  activation  of a 
71 metabolic  transcription factor [7-9]. Progressive  weakness nevertheless continues leading     to 
72 premature death between the second and fourth decade of life [10,   11]. 
73 
74 DMD  is  currently  an  incurable  disease,  although  encouraging  results  are  emerging   from 
75 different clinical trials,  and two personalised medicine  drugs,  eteplirsen and     ataluren,  have 
76 received conditional approval  in  the  US and  Europe,  respectively [10,  12-14].  A  number of 
77 other therapeutic approaches are being trialled  [15]. 
78 
 
79 The  diagnosis of  DMD is usually made by combining genetic, clinical and biochemical    tests 
80 and, in selected cases, by muscle biopsy. Levels of creatine kinase (CK), an enzyme involved 
81 in energy production and utilisation [16], are generally elevated in serum from   patients. 
82 Serum  CK  is  not  however  considered  to  be  a  reliable  circulating  biomarker  because  it is 
83 subject to fluctuations, mainly related to age and its modulation by physical activity [17, 18]. 
84 In addition, the progressive loss of muscle mass in DMD leads to a secondary reduction of 
85 CK  levels,  which  therefore  does  not  adequately  capture  the  progressive  nature  of        the 
86 condition.  Serum  matrix  metalloproteinase-9  (MMP-9)  is  being  studied  as  potential serum 
87 biomarker  for  dystrophinopathies  as  it  increases  significantly  with  age  in  patients’ serum. 
88 Nevertheless, its efficacy in monitoring disease progression and therapeutic response remains 
89 to be confirmed [19, 20]. Elevated levels of myomesin 3 (MYOM3) protein fragments have 
90 been  found   in   serum  from  DMD  patients  and  are   promising  candidate   for   monitoring 
91 experimental  therapies  [21].  Also,  urinary  levels  of  the  amino  terminal  fragments  of   the 
92 sarcomeric  protein titin  (N-ter titin) represent  a  potential  non-invasive  biomarker useful  for 
93 the diagnosis and to monitor the response to therapies [22]. Despite these encouraging results 
94 obtained  from  proteomic studies, there  is still  a pressing need for  novel,     non-invasive  and 
95 reliable  biomarkers  in DMD  sensitive  to disease progression and to assess  their efficacy    in 
96 response to therapeutic  intervention. 
 
97 
 
98 MicroRNAs are  small (~22  nucleotides) endogenous  non-coding RNAs  implicated  in   post- 
99 transcriptional  regulation  by  binding  the  3’  untranslated  region  (UTR)  of  their messenger 
100 RNA  (mRNA)  targets  [23].  Through  this  inhibitory  mechanism,  microRNAs  modulate the 
101 expression   of   genes   involved   in   pathways   regulating   skeletal   muscle   formation [24], 
102 differentiation  [25]  and  homeostasis  [26].  Moreover,  miRNA  dysregulation  in  serum   has 
103 been  associated  with  a  few  paediatric  neuromuscular conditions including DMD  and spinal 
104 muscular atrophy (SMA) and in their respective murine animal models [27-29]. MiRNAs are 
105 also present in urine where they are included in small microvesicles called exosomes (40-100 
106 nm) that protect them from degradation by RNases  [30]. 
 
107 
 
108 Exosomes  are  secreted  by  different  cell  types,  including  myoblasts,  allowing    cell-to-cell 
109 signalling by transferring their cargo molecules (mainly composed of miRNA, mRNA, lipids 
110 and proteins) [31]. Urinary exosomes have been investigated in urinary tract related diseases 
111 [32,  33],  breast  cancer  [34]  and  neurodegenerative  conditions  [35].  However,  there  is  no 
112 information on the contribution (if any) of skeletal muscle cells to the exosome population in 
113 urine,  nor  has  there been  any  study on  the  expression  of  urinary  miRNA  in  patients with 
114 muscular dystrophies. 
 
115 
 
116 In order to investigate the potential of urinary miRNAs as a novel non-invasive biomarker in 
117 DMD,  we  profiled their pool  isolated from  urinary exosomes of  ambulant and non-ambulant 
118 DMD patients and age matched controls and found >50 miRNAs downregulated in DMD 
119 patients.  From  these,  5  candidate  miRNAs  were  selected  for  further  validation,  based  on 
120 previous reports indicating their involvement in skeletal muscle related diseases   [36-41]. 
121 Finally, to test if there was any association between miRNA levels in urine and corticosteroid 
122 treatment, we studied the expression of the most dysregulated miRNAs in patients treated 
123 with prednisolone or deflazacort following a daily or intermittent   regimens. 
 
124 
 
125 
 
126 
 
127 
128 2. Materials & Methods 
129 2.1. Subject selection and urine  collection 
130 The  patients included  in this cross-sectional  study are  part  of  a  cohort  of DMD boys  taking 
 
131 part  in  a  multicenter  natural  history  study  registered  in  clinicaltrials.gov  (NCT02780492). 
 
132 Patients are assessed every six months according to a standardized protocol. Samples from 54 
 
133 patients  recruited  in  London,  Paris,  Newcastle  and  Leiden  were  analysed.  This  study  was 
 
134 approved  by  the  London-Bromley  Research  Ethics  Committee  (REC  12/LO/0442)  and   all 
 
135 Ethical  Committees  in  the  countries  involved.  All  patients  and  their  families  signed     the 
 
136 informed consent and  assent for the  Biobank for Neuromuscular Disorders  (approved by   The 
 
137 Hammersmith    and Queen    Charlotte’s and Chelsea Research Ethics Committee - 
138 06/Q0406/33). 
 
139 
 
140 Twenty healthy age-matched  volunteers  were recruited     from patients’ families and friends at 
141 Great Ormond Street Hospital. Urine samples (~ 20 ml) were collected on the day of the study 
142 visit (morning, not fasting) and immediately frozen at -80oC until analyses were    performed. 
143 The demographic, clinical data and corticosteroid therapy regimen administered are shown    in 
144 Supplementary Table 1. 
 
145 
 
146 2.2. Exosome isolation 
147 Exosomes were  extracted from  urine  using the miRCURY™  Exosome  Isolation  Kit – Cells, 
 
148 Urine & CSF (Exiqon) according to the manufacturer's instructions. Briefly, 1.6 mL of urine 
 
149 was centrifuged for 5 min at 10,000 x g to remove cell debris, and 1.5 mL of the resulting 
 
150 supernatant  was  incubated  overnight  at  4°C  after  the  addition  of  600  µl  of   Precipitation 
151 Buffer  B.  In  the  last  step,  the  supernatant  was  completely  removed  by  centrifugation (30 
152 minutes at 10,000 x g at 20°C), and the pellet was used for RNA   isolation. 
153 
 
154 2.3. RNA isolation 
 
155 To isolate microRNAs contained in exosomes, the miRCURY™ RNA Isolation Kit – Cell & 
 
156 Plant  (Exiqon)  was  used  according  to  the  manufacturer's  instructions.  Briefly,  the    pellet 
 
157 obtained from the exosome isolation was re-suspended in 350 µl lysis solution containing 
 
158 1.25 µl MS2 RNA carriers (Roche) and 1 µl of synthetic UniSp2, UniSp4, UniSp5 RNA 
 
159 spike-in mix (Exiqon) required to monitor the isolation efficiency. After vortexing, 200 µl of 
 
160 96  –  100%  ethanol  were  added  to  the  solution,  then  it  was  transferred  onto  a  Mini Spin 
 
161 Column and centrifuged for 1 minute at > 3500 x g. Subsequently, the column was subjected 
 
162 to three washing cycles by adding 400 µl of Wash Solution and centrifuged for 1 minute at 
 
163 14000 x g. 
 
164 Total RNA, including small RNAs from exosomes, was obtained by adding 100 µl of Elution 
 
165 Buffer followed by two centrifugation steps (2 minutes at 200 x g and 1 minute    at 14000 x g). 
 
166 
 
167 2.4. microRNA profiling 
 
168 Profiling  analysis   were   performed   on   urinary  exosomes   from   15   healthy   controls, 15 
 
169 ambulant DMD and 17 non-ambulant DMD  patients. 
 
170 RT: cDNA was generated by reverse transcription using the Universal cDNA synthesis kit II 
 
171 (Exiqon) according to the manufacturer's instructions. A fixed volume of 4 µl of total RNA (5 
 
172 ng/µl)/sample  was used as  the  starting material. The  quality of  the  samples was  verified  by 
 
173 adding to the mix 1 µl of synthetic UniSp6/cel-miR-39 spike-in mix   (Exiqon). 
 
174 qPCR:  The  reactions  were  performed  using  a  miRCURY  LNA™  Pick-&-Mix microRNA 
 
175 PCR SYBR green- ased panels (containing primers for 87 urinary miRNAs, Table S2) and a 
 
176 StepOne Plus 96 well Real-time PCR System (ThermoFisher). A total volume of 10 µl of 
177 cDNA/sample   was   added   in   the   mix   for   the   profiling   analysis,   according   to      the 
178 manufacturer’s  instructions (Exiqon). 
179 Normalization:  Expression  analysis  was  performed  using  the  GeneX  software     (Exiqon). 
180 Global  mean value  normalisation using the global  mean of  all  miRNAs that  had CT   values 
181 <34 for the microRNA  profiling. 
182 Heatmaps: Heatmaps and average linkage hierarchical clusters showing the miRNA    signature 
183 pattern within the samples were designed on http://www1.heatmapper.ca/expression/    [42]. 
 
184 
 
185 2.5. microRNA validation 
186 In the validation step, we studied the expression of five selected candidates (miR-21-5p, miR- 
 
187 22-3p,  miR-23 -3p,  miR-29c-3p,  and  miR-103a-3p)  in  urinary  exosomes  from  20 controls 
 
188 (average  age=9  years),  31  ambulant  (average  age=8  years)  and  23  non-ambulant     DMD 
 
189 patients (average age=14 years), including the samples used for miRNA   profiling. 
 
190 RT:  cDNA  was  generated  by reverse  transcription using the  TaqMan™ Advanced   miRNA 
 
191 cDNA  Synthesis  Kit  (ThermoFisher)  according  to  the  manufacturer's  instructions.  2  µl of 
 
192 total RNA (5 ng/µl)/sample was used as the starting material. The quality of the samples was 
 
193 verified by adding to the mix 1 µl of synthetic UniSp6/cel-miR-39 spike-in mix    (Exiqon). 
 
194 qPCR:  The  reactions  were  performed  using  a  qPCR  TaqMan  small  RNA  Assay       (Life 
 
195 Technology) and a StepOne Plus 96 well Real-time PCR System   (ThermoFisher). 
 
196 Normalization: Normalisation using the ∆∆Ct method to a stable reference gene (miR-16c- 
 
197 5p) detected by NormFinder algorithm were performed at the validation stages [43,   44]. 
 
198 
 
199 2.6. Negative controls 
200 Before the exosomal miRNA isolation, we added three synthetic non-human spike    in 
 
201 controls, UniSp2, UniSp4 and UniSp5, in the lysis buffer in order to monitor the efficiency of 
202 the process. As suggested in the manufacturer’s protocol, UniSp2 should amplify at the    level 
 
203 of highly expressed microRNAs, whereas UniSp4 should amplify approximately 6.6    cycles 
204 later and UniSp5 might not always be  detectable. 
 
205 
 
206 Our data confirm that the isolation process in all samples was successful. The   detected 
207 average cycle    threshold (Ct) for UniSp2 was 21.46 and UniSp4 was amplified for an average 
208 of 6.56 cycles later than UniSp2 (average Ct=28.02). Little or no expression of UniSp5    was 
209 detected across the samples. 
 
210 
 
211 Two additional synthetic controls, cel-miR-39 and UniSp6, were added to the   mix 
212 immediately before the retro-transcription. These two controls were expressed in all    samples, 
213 indicating that the cDNA used for the profiling was of high quality (Fig   S1). 
 
214 
 
215 2.7. Statistical analysis 
216 The Mann-Whitney test was used for statistical analysis of two groups of data, whereas One- 
 
217 way analysis of variance was used to determine statistical significance between three    and four 
 
218 groups  of  subjects.  The Bonferroni  test  for the correction  of  the  p-value was performed for 
 
219 multiple comparisons (profiling).  Data are  presented as mean  ± standard error  of  the     mean 
220 (Mean  ±  SEM).  GraphPad  Prism  7.0  software  was  used  for  statistical  analysis  and graph 
221 design. 
 
222 
 
223 3. Results 
 
224 3.1. Exosomal microRNA profiling in urine of DMD patients and healthy    controls 
 
225 34 microRNAs were either undetected or weakly expressed and were excluded from   the 
 
226 study. 53 miRNAs were detected in at least 60% of the samples and   included in subsequent 
227 statistical comparisons. There was an overall trend of miRNA downregulation in   DMD 
 
228 patients (ambulant and non-ambulant) compared to healthy controls (Fig S2). No    microRNAs 
 
229 were upregulated in DMD compared to  controls. 
 
230 
 
231 3.1.1. miRNA profiling in urinary exosomes from all DMD patients compared to    healthy 
 
232 controls 
 
233 After Bonferroni correction of the p-value, three miRNAs were significantly   different 
 
234 between DMD patients and controls. There was significant downregulation of    miR-21-5p 
 
235 (P<0.001, Fig 1A), miR-22-3p (P<0.001, Fig 1B) and miR-29c-3p (P<0.001,    Fig 1C) when 
 
236 the DMD patients group (ambulant and non-ambulant) was compared to   controls. 
 
237 
 
238 3.1.2. miRNA profiling in urinary exosomes from ambulant DMD patients compared    to 
 
239 healthy controls 
 
240 To investigate the possibility that the levels of urinary miRNA might be influenced   by the 
 
241 ambulatory status of the DMD boys, further statistical analyses were carried out by    stratifying 
 
242 the DMD samples into 15 ambulant (A) and 17 non-ambulant (NA). Of three miRNAs    that 
 
243 were significantly downregulated in DMD compared to controls, only miR-29c-3p   was 
 
244 significantly downregulated (P<0.01, Fig 2A) in ambulant DMD patients compared    to the 
 
245 healthy controls. There was significant downregulation of two additional identified in the    first 
 
246 part of the study, miRNAs - miR-92a-3p (P<0.01, Fig 2B) and miR-103a-3p (P<0.01,    Fig 
 
247 2C) when ambulant patients were compared to healthy   controls. 
 
248 
 
249 3.1.3. Expression of miR-29c-3p, miR-92a-3p and miR-103a-3p correlates with    preserved 
 
250 ambulation in DMD 
251 Receiving operating characteristic (ROC) curves were generated to test sensitivity   and 
252 specificity of miR-29c-3p, miR-92a-3p and miR-103a-3p. Regarding miR-29c-3p,    when 
253 comparison was made between the healthy controls and the group including all   patients 
254 (A+NA), the area under the curve (AUC) was 0.8086 (95%CI=0.6678-0.9494, Fig    3A). 
255 When comparison was made between healthy controls and ambulant patients (A), the    AUC 
256 was 0.8267 (95%CI=0.6786-0.9748, Fig 3B). These results indicate that miR-29c-3p    levels 
257 better correlate with preserved ambulation in DMD patients. Similarly, for miR-103a-3p,   the 
258 areas under the curves (AUC) were 0.8244 (95%CI=0.6914-0.9575, Fig 3C) in    patients 
259 (A+NA) and 0.8533 (95%CI=0.6966-1.01, Fig 3D) in ambulant patients. In addition,    AUC 
260 values for miR-92a-3p, were 0.7126 (95%CI=0.5465-0.8788, Fig 3E) in patients    (A+NA) 
261 and 0.8178 (95%CI=0.6586-0.977, Fig 3F) in ambulant patients. All the AUC    results indicate 
262 that miR-29c-3p, miR-103a-3p and miR-92a-3p levels correlate best with   preserved 
263 ambulation in DMD patients. 
 
264 
 
265 3.1.4. miRNA profiling in urinary exosomes from non-ambulant DMD patients    compared to 
266 healthy controls 
267 There were no significant differences in the levels of urinary miRNAs between    non-ambulant 
268 DMD patients and healthy  controls. 
 
269 
 
270 3.1.5. miRNA profiling in urinary exosomes from DMD ambulant compared to DMD    non- 
271 ambulant patients 
272 There were no significant differences in miRNA expression between ambulant and   non- 
273 ambulant DMD patients. 
 
274 
 
275 3.2. Selection of microRNA candidates for further validation   studies 
276 From the most dysregulated miRNA identified through profiling analysis, we selected   5 
277 miRNAs for further validation studies (miR-21-5p, miR-22-3p, miR-23 -3p, miR-29c-3p    and 
278 miR-103a-3p).   Among these, miR-23 -3p was downregulated in all the  statistical 
279 comparisons, although the significance was eventually lost when applying the    Bonferroni 
280 corrections. Moreover, the dysregulation of miR-21, miR-22 and miR-29 in   muscular 
281 dystrophy has already been reported in literature (Table  1). 
 
282 
 
283 Table 1 
284 Selected candidate involvement in skeletal  muscle 
 
microRNA Previous findings Model 
miR-29 downregulated in mdx mouse model of DMD [36] mdx muscles 
loss of miR-29 in myoblasts contributes to dystrophic muscle 
pathogenesis[36] 
mdx primary 
myoblasts 
myogenic factor[39] C2C12 cells 
reduced in DMD patients[37] DMD patient 
muscle and 
myoblasts 
downregulated in quiescent satellite cells during myogenesis in vitro 
[38] 
Human satellite 
cells 
miR-22 upregulated in Facio scapulo humeral muscular dystrophy 
(FSHD)[40] 
FSHD patient 
myoblasts 
upregulated in Limb-girdle muscular dystrophy type 2D 
(LGMD2D)[41] 
Sgca-null mouse 
serum 
miR-21 increased in DMD[37] DMD patient 
muscle and 
myoblasts 
285 
 
286 3.2.1. Bioinformatic prediction of the  targets 
287 In order to predict the target genes of the 5 selected candidates, Pathway Analysis   with the 
288 online tool DianaMirpath [45] was performed.   The algorithm allows the identification   not 
289 only of the potential target genes of a specific microRNA, but also to locate   them to the 
290 related Kyobo Encyclopedia of Genes and Genomes (KEGG) pathway   [46]. 
291 As showed in Table S3, our miRNA affected pathways included the following:    extracellular 
292 matrix (ECM)-receptor interaction, focal adhesion, ErbB signaling pathway, TGF-   eta 
293 signaling pathway, mTOR signaling pathway, apoptosis and MAPK signaling   pathway. 
294 
 
295 Table S3 
 
296 Predicted target genes of the candidate  microRNAs 
 
 
microRNA Predicted target genes from DIANA miRPath 
 
p-value 
 
KEGG pathway 
 
 
 
 
 
 
 
 
hsa-miR-21-5p 
ITGB8, THBS1, COL5A2, CD47 1.05E-11 ECM-receptor  interaction 
ERBB2, ITGB8, THBS1, BCL2, 
EGFR, PTK2, PIK3R1, 
PDGFD, VEGFA, PTEN, 
COL5A2 
 
2.12E-06 
 
Focal adhesion 
ERBB2, EGFR, PTK2, MYC, 
PIK3R1 2.31E-06 ErbB signaling pathway 
TGFBR1, ZFYVE16, MYC, 
TGFB2, TGFBR2, BMPR2 8.30355E-05 
TGF-beta signaling 
pathway 
TSC1, PIK3R1, RPS6KA3, 
VEGFA, PTEN, RRAGC 0.000527381 mTOR signaling pathway 
BID, BCL2, APAFI, PIK3R1, 
FAS 0.007398499 Apoptosis 
TGFBR1, EGFR, MAP3K1, 
RASA1, RASGRP1, MYC, 
DUSP8, FAS, RPS6KA3, 
TGFB2, MAP3K2, RASGRP3, 
MKNK2, TGFBR2 
 
 
0.0173412 
 
 
MAPK signaling pathway 
 
hsa-miR-22-3p 
 
SP1, BMP7 8.30355E-05 
TGF-beta signaling 
pathway 
PRKACA 0.007398499 Apoptosis 
PRKACA 0.0173412 MAPK signaling pathway 
hsa-miR-23b-3p STAT5B 2.31E-06 ErbB signaling pathway 
 
 
 
 
 
hsa-miR-29c-3p 
COL3A1, COL4A2, COL1A1, 
COL1A2, LAMC1, Col6a2, 
COL4A1 
 
1.05E-11 
 
ECM-receptor  interaction 
BCL2, COL3A1, JUN, COL4A2, 
COL1A1, COL1A2, LAMC1, 
AKT3, Col6a2, VEGFA, 
COL4A1 
 
2.12E-06 
 
Focal adhesion 
AKT2, JUN,AKT3 2.31E-06 ErbB signaling pathway 
AK2, AKT3, VEGFA 0.000527381 mTOR signaling pathway 
BCL2, AK2, AK3 0.007398499 Apoptosis 
AKT2, JUN, AKT3 0.0173412 MAPK signaling pathway 
 
 
 
hsa-miR-103a-3p 
ITGA2 1.05E-11 ECM-receptor  interaction 
BCL2, ZYX, ITGA2 2.12E-06 Focal adhesion 
ABL2, RPS6KB1 2.31E-06 ErbB signaling pathway 
 
ACVR2B, SMAD7, RPS6KB1 8.30355E-05 
TGF-beta signaling 
pathway 
RPS6KB1 0.000527381 mTOR signaling pathway 
FGF2, MAP3K7 0.007398499 Apoptosis 
 FGF2, MAP3K7 0.0173412 MAPK signaling pathway 
297 
 
298 3.2.2. Validation of the  candidates 
299 The Normfinder [44] algorithm was used to discover the most suitable reference gene    (among 
300 the 87 microRNAs analysed at the profiling stage) which was miR-16   -5p. 
 
301 
 
302 3.2.3. miR-29 downregulation in ambulant DMD   patients 
303 The significant dysregulation of miR-29c-3p detected in the original profiling step   was 
304 confirmed further, with 54 DMD patients (including both ambulant and   non-ambulant) 
305 having lower miR-29c-3p levels compared to the 20 healthy controls (P<0.05, Fig 4A).     This 
306 miRNA remained significantly downregulated when only ambulant DMD patients   were 
307 compared to the healthy controls (P<0.05, Fig  4B). 
 
308 
 
309 We also compared the non-ambulant DMD patients to controls, and although we observed    a 
310 trend towards downregulation, this was not statistically significant (Fig 4C). These   results 
311 indicate that the extent of miR-29c-3p downregulation is more marked in ambulant    than in 
312 non-ambulant DMD patients, but not sufficiently different between the 2 groups to be   of 
313 significance. 
 
314 
 
315 Moreover, to determine if miR-29c-3p levels correlated with the age of DMD patients,   we 
316 performed linear regression analyses.  Although the levels of miR-29c-3p in urine of   DMD 
317 patients decrease with age, there was no significant correlation between their expression   and 
318 the age of the patients (Fig  S3A). 
 
319 
 
320 3.2.4. miR-23b-3p and miR-21-5p downregulation in non-ambulant DMD   patients 
321 There was a significant downregulation of miR-23 -3p (P<0.01, Fig 4F) and    miR-21-5p 
322 (P<0.05, Fig 4I) in non-ambulant DMD patients compared with the controls but not   in 
323 controls vs all DMD patients (Fig 4D, 4G), nor in controls vs ambulant DMD patients    (Fig 
324 4E, 4H) . There was no significant difference in the relative expression of the   other selected 
325 candidates (miR-22-3p and miR-103a-3p) in patients compared to the controls; hence,    they 
326 were excluded from further analysis. Finally, as for miR-29c-3p, linear regression   analyses 
327 did not show a significant correlation between miR-23 -3p and miR-21-5p    expression and 
328 age of patients (Fig S3B,  S3C). 
 
329 
 
330 In summary, validation analysis confirmed the significant downregulation of 3   urinary 
331 exosomal microRNAs: - miR-29c-3p in DMD ambulant, miR-23 -3p and miR-21-5p    in 
332 DMD non-ambulant patients  respectively. 
 
333 
 
334 3.3. miRNA response to the corticosteroid  therapy 
335 In order to determine if there were differences in the selected candidate miRNA    expression 
 
336 profiles between patients on different corticosteroid regimens, statistical comparisons   were 
 
337 performed on patients receiving prednisolone vs deflazacort, and on daily versus    intermittent 
338 (10/10) steroid regimens. 
 
339 
 
340 3.3.1. Deflazacort compared to  Prednisolone 
341 When comparisons were made between the two different steroid regimens (deflazacort    vs 
342 prednisolone), none of the selected candidates showed significant differences (S4   Fig). 
 
343 
 
344 3.3.2. Daily compared to intermittent  regimen 
345 To test if there was any association between expression of    selected candidates in urine and 
 
346 corticosteroid regimen, statistical comparisons were made among three groups:   healthy 
 
347 controls, patients undergoing a daily treatment and those receiving the drugs   intermittently 
 
348 (regardless of the corticosteroid administered).   Interestingly, miR-29c-3p was  significantly 
 
349 downregulated in patients undergoing intermittent corticosteroid treatment compared   to 
 
350 controls, but not in those receiving daily treatment (Fig 5D).   There was no  correlation 
 
351 between the expression levels of the remaining miRNAs: miR-21-5p (Fig 5A),    miR-22-3p 
 
352 (Fig 5B), miR-23b-3p (Fig 5C) and miR-103a-3p (Fig 5E) and the    corticosteroid regimen. 
 
353 
 
354 
 
355 
 
356 
357 4. Discussion 
 
358 
 
359 Our study is the first to investigate the expression of exosomal urinary miRNAs in    DMD 
360 patients or in any form of muscular dystrophy. In the last decade, several studies   have 
361 focused on differential miRNA expression in DMD, providing new insights into their role    in 
362 the modulation of pathological signalling pathways [47, 48], and also indicating   their 
363 potential role as non-invasive biomarkers to monitor disease progression [29,   49]. 
 
364 
 
365 We show that miR-29 was significantly downregulated in ambulant DMD patients and    that 
366 miR-23 and miR-21 were significantly downregulated in non-ambulant DMD    patients 
367 compared to age matched controls.   Contrary to several studies focused on noncoding   RNA 
 
368 dysregulation in serum from DMD patients and mdx mice, in which a large number   of 
369 miRNAs were significantly upregulated compared to controls [27, 50-52], we found    no 
370 upregulated miRNAs in urine from DMD  patients. 
 
371 
 
372 The downregulation of mir-29c-3p, a member of the miR-29 family, which is composed    of 
 
373 five miRNAs having identical seed regions (thus sharing the same target genes) [53]     has 
374 been reported in muscles from DMD patients [37] and mdx mice [36]. This miRNA is a key 
 
375 promoter of skeletal muscle regeneration in mdx mice, and myogenic differentiation   of 
 
376 primary mdx myoblasts in vitro [36]. Moreover, miR-29 agonists have potential    therapeutic 
 
377 application in a broad spectrum of fibrotic diseases [54], as shown by the    demonstration that 
 
378 systemic delivery of miR-29 significantly reduced diaphragm fibrosis in mdx mice   [36]. 
 
379 
 
380 Fibrosis is a particular hallmark of DMD, and    contributes to the skeletal and cardiac muscle 
 
381 pathology by altering the functionality [55, 56]. In DMD, TGFβ is considered to be one of the 
382 strongest profibrogenic factors. It is stored in the extracellular matrix and when activated,    as a 
383 consequence of tissue damage, exerts its effects through binding to the TGFβ Type I   and 
384 TGFβ Type II receptors [57, 58].     In the mdx diaphragm, TGF-β1 upregulation occurs at early 
385 stages of fibrogenesis [36, 58, 59].  In DMD patients, TGFβ-1 triggers the fibrotic    process, 
386 and reaches peak levels in muscles during the early stages of the disease (6 years)    promoting 
387 a massive connective tissue proliferation. After this phase, TGF-β1 levels decline while   the 
388 proliferation process continues [60]. TGFβ promotes fibrosis in mdx skeletal muscle   by 
389 inhibiting mir-29 expression [36] which is a key player in controlling    ECM modifications 
390 [61]. Other evidence implicating TGF-β1 in promoting fibrosis by inhibiting   miR-29 
391 expression comes from studies on pulmonary fibrosis, which showed that miR-29    modulates 
392 the fibrotic process by binding a large number of genes involved in ECM synthesis   and 
393 remodelling including COL1A1, MMP2 and MMP14 [62]. Moreover, previous    studies 
394 focused on renal fibrosis showed that this process was correlated with the loss of   miR-29 
395 mediated by a TGFβ/SMAD3 dependent mechanism  [63]. 
 
396 
 
397 We speculate that reduced levels of miR-29 observed in the ambulant DMD boys    are the 
398 result of the progressive fibrosis, promoted by TGF-β1 signalling, which characterises   the 
399 early stages of the disease. Interestingly, we found that miR-29 levels are affected   by the 
400 regimen of corticosteroid therapy, drugs which are prescribed as part of the standards    of care 
401 in DMD patients [64, 65]. In particular, we found significant downregulation of    miR-29 in 
402 patients receiving the intermittent steroid regimen but not in those receiving a daily    treatment, 
403 indicating that a constant administration of corticosteroids might be more efficient   in 
404 maintaining miR-29 levels closer to those in healthy controls, and hence    in slowing down the 
405 fibrotic process. This hypothesis is supported by the recent report of the inhibitory action    of 
406 prednisolone on TGF-β1, a repressor of miR-29 [36],  in mdx diaphragm [66].   Since   miR-29 
407 downregulation in muscle [37] was mirrored in urine from DMD patients and    its levels in 
 
408 urine were normalised by corticosteroid therapy, this microRNA represents to date, the    most 
 
409 promising urinary non-invasive biomarker for  DMD. 
 
410 
 
411 In our validation studies, we found a significant downregulation of miR-23 -3p in   non- 
 
412 ambulant patients. This is the first time miR-23 has been reported to be    implicated in DMD, 
 
413 and consequently, its role in the disease is still unclear. However, a link   between miR-23 
 
414 and TGFβ have been reported in liver, where it downregulates Smad genes in mouse   fetal 
 
415 liver cells and consequently the TGFβ signalling [67] and also in murine airway   smooth 
 
416 muscle, where it controls the proliferation of the cells through inactivating TGFβ   signalling 
 
417 [68].     Moreover, it has been shown that fibrosis in human fibroblasts is induced by TGFβ via 
 
418 the PAK2 pathway which in turn, stimulates matrix synthesis through the activation of   the 
 
419 Smad1 protein [69]. As miR-23  targets a large number of genes in human,    including PAK2 
 
420 [70], we speculate that it might counteract the fibrotic process in DMD, through the   TGFβ 
 
421 signaling inhibition.   However further studies aimed at investigating the association   between 
 
422 miR-23  and fibrosis are needed to confirm this hypothesis and to address its involvement    in 
 
423 DMD pathogenesis. 
 
424 
 
425 We also found a significant downregulation of miR-21 in urine of non-ambulant   DMD 
 
426 patients. Our results differ those from Zanotti et al, where miR-21 was upregulated    in muscle 
 
427 biopsies (quadriceps) and fibroblasts from DMD patients aged 1-8 years [37].   MiR-21 
 
428 promotes TGFβ-1 related fibrosis by inducing the transdifferentiation of fibroblasts   to 
 
429 myofibroblasts [37] in which collagen synthesis is augmented leading to fibrosis   [71]. 
 
430 Further investigations aimed at clarifying the mechanisms underlying differential   miR-21 
 
431 expression observed in muscle [37] and urine will be beneficial to understand its contribution 
432 in DMD.  In particular studies aimed at determining the source of exosomes    would clarify 
433 whether they are synthesised by the renal epithelial cells as proposed by Pisiktun    et al. [72], 
434 or produced by other cells elsewhere in the body and merely transit the renal    epithelium 
435 before being released into urine. Whether urinary exosomes actually originate    from cells 
436 within skeletal muscle, or other organs [73-75] is not  known. 
 
437 
 
438 
 
439 4.1. Conclusions 
440 Our findings indicate that exosomal urinary miR-29c-3p, miR-23 -3p and miR-21-5p    are 
441 promising novel non-invasive biomarkers for DMD, and that miR-29c-3p levels   are 
442 differentially affected by different steroid regimens, supporting the antifibrotic effect   that 
443 steroid therapy have, and indicating for the first time that the determination of   urinary 
444 miRNA levels allow to capture differences between different steroids regimens, which   likely 
445 reflect the differences in clinical benefit between daily vs intermittent steroids therapies   [76, 
446 77]. 
 
447 
 
448 4.2. Executive Summary 
 
449 • Duchenne muscular dystrophy (DMD) is an X-linked and progressive neuromuscular 
 
450 disorder  affecting  1  in  5000  newborn  males  leading  to  progressive  skeletal muscle 
 
451 wasting and death. 
 
452 
 
453 • Levels  of  creatine  kinase  (CK),  are  generally  elevated  in  serum  from        patients, 
 
454 however this enzyme is not considered to be a reliable circulating biomarker because 
455 it  is  subject  to  fluctuations,  mainly  related  to  age  and  its  modulation  by  physical 
 
456 activity. 
 
457 
 
458 • There is still a pressing need for novel, non-invasive and reliable biomarkers in DMD 
 
459 that are sensitive to disease progression and able to reliably monitor the efficacy of 
 
460 any therapeutic intervention. 
 
461 
 
462 • MicroRNAs are small (~22 nucleotides) endogenous non-coding RNAs implicated in 
 
463 post-   transcriptional   regulation   of   their   messenger   RNA   (mRNA)   targets,  that 
 
464 modulate  the  expression  of  genes  involved  in  pathways  regulating  skeletal  muscle 
 
465 formation, differentiation and  homeostasis. 
 
466 
 
467 • MiRNAs  are  present in urine  where  they are  included in small microvesicles    called 
 
468 exosomes (40-100 nm) that protect them from degradation by   RNases. 
 
469 
470 
 
471 • We studied the signature of 87 urinary miRNAs from controls (n =20), ambulant   (n = 
 
472 31) and non-ambulant (n = 23) DMD  patients. 
 
473 
 
474 • MiR-29c-3p is significantly downregulated in ambulant DMD patients compared   to 
 
475 age matched controls and its levels are affected by different steroid   regimens. 
 
476 
477 • MiR-23b-3p and miR-21-5p are significantly downregulated in non-ambulant   DMD 
 
478 patients compared to age matched controls. 
 
479 
480 4.3. Future perspective 
481 
482 Changes in urinary miRNA levels are a potential non-invasive means of determining    disease 
483 progression and the efficacy of any therapeutic intervention in neuromuscular conditions    such 
484 as DMD. 
 
485 
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724 Supplementary Fig. 2. Expression profiles of exosomal microRNAs in the urine   of DMD 
725  patients and healthy controls. Heat map and average linkage hierarchical   clusters showing 
726  the miRNA signature pattern within the samples (n=15 controls, n=15 ambulant   DMD, n=17 
727  non-ambulant DMD). Upregulated miRNAs are depicted in green and downregulated   in red. 
728  A prevalence of downregulated miRNAs is evident in the DMD population   when compared 
729  to controls. 
730 
 
731 Fig. 1. Expression of miR-21-5p, miR-22-3p and miR-29c-3p in urine samples    from 
 
732 DMD patients. 
 
733 Expression of the three microRNA in urinary exosomes isolated from healthy controls    (n=15) 
 
734 ambulant DMD patients (n=15) and non-ambulant DMD patients (n=17). There    was 
 
735 significant downregulation of miR-21-5p (A), miR-22-3p (B) and miR-29c-3p (C)   in the 
736 DMD patient group (ambulant and non-ambulant patients) compared to controls.   Data are 
737 presented as Mean ± SEM. ***p< 0.001. GMV= global mean   value. 
738 
 
739 Fig. 2. Expression of miR-29c-3p, miR-92a-3p and miR-103a-3p in urine samples    from 
 
740 ambulant DMD patients. 
 
741 Expression of the three microRNAs in urinary exosomes isolated from healthy    controls 
 
742 (n=15) and ambulant DMD patients (n=15). There was significant downregulation   of miR- 
743 29c-3p (3A), miR-92a-3p (3B) and miR-103a-3p (3C) in the DMD patients    (including both 
744 ambulant and non-ambulant patients) compared to controls. Data are presented as   Mean ± 
745 SEM. **p< 0.01. GMV= global mean  value. 
746 
 
747 Fig. 3. ROC curve analysis of urinary miR-29c-3p, miR-92a-3p and   miR-103a-3p. 
 
748 ROC curves based on miR-29c-3p urinary levels, for differentiating between the   group 
 
749 including all the DMD (n=32) (A) and ambulant patients (n=15) (B) . The same analysis    was 
 
750 performed for miR-103a-3p (C, D) and miR-92a-3p (E,   F). 
 
751 
 
752 Fig. 4. Validated expression of miR-29c-3p, miR-23b-3p and miR-21-5p in   urine 
 
753 samples from DMD patients. 
 
754 Expression of miR-29c-3p, miR-23 -3p and miR-21-5p in urinary exosomes   isolated from 
755 healthy controls (n=20) ambulant (n=31) and non-ambulant (n=23) DMD patients.    There was 
756 significant downregulation of miR-29c-3p in patients compared to controls (A) and   in 
757 ambulant patients compared to controls (B). MiR-23 -3p was significantly   downregulated in 
758 non-ambulant patients compared to controls (F). MiR-21-5p was   significantly downregulated 
759 in non-ambulant patients compared to controls (I) Data are presented as Mean ±   SEM. *p< 
760 0.05; **p< 0.01. 
761 
762 Supplementary Fig. 3. Lack of correlation between miR-29c-3p, miR-23b-3p and    miR- 
 
763 21-5p expression with age in DMD patients. 
 
764 Linear regression analyses between the levels of and miR-29c-3p (A), miR-23 -3p (B)    and 
 
765 miR-21-5p (C), in urine and the Age of DMD patients (N=54). The regression    line is 
 
766 presented. 
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768 Fig. 5. Effects of different corticosteroid regimens on candidate miRNA    expression. 
 
769 Expression of miR-21-5p (A), miR-22-3p (B), miR-23 -3p (C), miR-29c-3p    (D) and miR- 
 
770 103a-3p (E) in urinary exosomes isolated from healthy controls (n=20), DMD    patients treated 
771 with any daily corticosteroids (n=25) and DMD patients treated with any   intermittent 
 
772 corticosteroids (n=18). Data are presented as Mean ± SEM. *p<   0.05. 
 
773 
 
774 Supplementary Fig. 1 Expression of the synthetic controls. UniSp6 (orange) and    cel-miR- 
 
775 39 (light blue) expression in the samples (n=47) used for microRNA profiling. The   x-axis 
 
776 represents the samples (both patients and controls) while the y-axis represents Ct   values. 
 
777 
 
778 Supplementary Fig. 4. Validated microRNA expression in DMD patients    receiving 
 
779 different corticosteroids (prednisolone compared to   deflazacort). 
 
780 Expression of miR-21-5p (A), miR-22-3p (B), miR-23b-3p (C), miR-29c-3p (D) and    miR- 
 
781 103a-3p (E) in urinary exosomes isolated from healthy controls (n=20), Prednisolone    treated 
 
782 DMD patients (n=36) and Deflazacort treated DMD patients (n=7). Data are presented    as 
 
783 Mean ± SEM. 
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Fig. 1. Expression of miR-21-5p, miR-22-3p and miR-29c-3p in urine samples from DMD patients. 
Expression of the three microRNA in urinary exosomes isolated from healthy controls (n=15) ambulant DMD 
patients (n=15) and non-ambulant DMD patients (n=17). There was significant downregulation of miR-21- 
5p (A), miR-22-3p (B) and miR-29c-3p (C) in the DMD patient group (ambulant and non-ambulant patients) 
compared to controls. Data are presented as Mean ± SEM. ***p< 0.001. GMV= global mean value. 
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Fig. 2. Expression of miR-29c-3p, miR-92a-3p and miR-103a-3p in urine samples from ambulant DMD 
patients. 
Expression of the three microRNAs in urinary exosomes isolated from healthy controls (n=15) and ambulant 
DMD patients (n=15). There was significant downregulation of miR-29c-3p (3A), miR-92a-3p (3B) and miR- 
103a-3p (3C) in the DMD patients (including both ambulant and non-ambulant patients) compared to 
controls. Data are presented as Mean ± SEM. **p< 0.01. GMV= global mean value. 
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Fig. 3. ROC curve analysis of urinary miR-29c-3p, miR-92a-3p and miR-103a-3p. 
ROC curves based on miR-29c-3p urinary levels, for differentiating between the group including all the DMD 
(n=32) (A) and ambulant patients (n=15) (B). The same analysis was performed for miR-103a-3p (C, D) 
and miR-92a-3p (E, F). 
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Fig. 4. Validated expression of miR-29c-3p, miR-23b-3p and miR-21-5p in urine samples from DMD patients. 
Expression of miR-29c-3p, miR-23b-3p and miR-21-5p in urinary exosomes isolated from healthy controls 
(n=20) ambulant (n=31) and non-ambulant (n=23) DMD patients. There was significant downregulation of 
miR-29c-3p in patients compared to controls (A) and in ambulant patients compared to controls (B). MiR- 
23b-3p was significantly downregulated in non-ambulant patients compared to controls (F). MiR-21-5p was 
significantly downregulated in non-ambulant patients compared to controls (I) Data are presented as Mean 
± SEM. *p< 0.05; **p< 0.01. 
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Fig. 5. Effects of different corticosteroid regimens on candidate miRNA expression. Expression of miR-21-5p 
(A), miR-22-3p (B), miR-23b-3p (C), miR-29c-3p (D) and miR-103a-3p (E) in urinary exosomes isolated 
from healthy controls (n=20), DMD patients treated with any daily corticosteroids (n=25) and DMD patients 
treated with any intermittent corticosteroids (n=18). Data are presented as Mean ± SEM. *p< 0.05. 
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Supplementary Fig. 1 Expression of the synthetic controls. UniSp6 (orange) and cel-miR-39 (light blue) 
expression in the samples (n=47) used for microRNA profiling. The x-axis represents the samples (both 
patients and controls) while the y-axis represents Ct values. 
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Supplementary Fig. 2. Expression profiles of exosomal microRNAs in the urine of DMD patients and healthy 
controls. Heat map and average linkage hierarchical clusters showing the miRNA signature pattern within 
the samples (n=15 controls, n=15 ambulant DMD, n=17 non-ambulant DMD). Upregulated miRNAs are 
depicted in green and downregulated in red. A prevalence of downregulated miRNAs is evident in the DMD 
population when compared to controls. 
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Supplementary Fig. 3. Lack of correlation between miR-29c-3p, miR-23b-3p and miR-21-5p expression with 
age in DMD patients. 
Linear regression analyses between the levels of and miR-29c-3p (A), miR-23b-3p (B) and miR-21-5p (C), in 
urine and the Age of DMD patients (N=54). The regression line is presented. 
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Supplementary Fig. 4. Validated microRNA expression in DMD patients receiving different corticosteroids 
(prednisolone compared to deflazacort). 
Expression of miR-21-5p (A), miR-22-3p (B), miR-23b-3p (C), miR-29c-3p (D) and miR-103a-3p (E) in 
urinary exosomes isolated from healthy controls (n=20), Prednisolone treated DMD patients (n=36) and 
Deflazacort treated DMD patients (n=7). Data are presented as Mean ± SEM. 
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Table 1. Selected candidate involvement in skeletal   muscle. 
 
 
 
microRNA Previous findings Model 
miR-29 downregulated in mdx mouse model of DMD [36] mdx muscles 
loss of miR-29 in myoblasts contributes to dystrophic muscle 
pathogenesis[36] 
mdx primary 
myoblasts 
myogenic factor[39] C2C12 cells 
reduced in DMD patients[37] DMD patient 
muscle and 
myoblasts 
downregulated in quiescent satellite cells during myogenesis in vitro 
[38] 
Human satellite 
cells 
miR-22 upregulated in Facio scapulo humeral muscular dystrophy 
(FSHD)[40] 
FSHD patient 
myoblasts 
upregulated in Limb-girdle muscular dystrophy type 2D 
(LGMD2D)[41] 
Sgca-null mouse 
serum 
miR-21 increased in DMD[37] DMD patient 
muscle and 
myoblasts 
 S1 Table. Demographic and clinical characteristics of the samples used for profiling and 
validations. 
 
 
 
Sample 
 
Amb 
Age at 
sampling 
 
Steroids 
 
Steroids regime 
 
Genetic mutation 
CONTROL 1 A 4 n/a n/a no 
CONTROL 2 A 4 n/a n/a no 
CONTROL 3 A 5 n/a n/a no 
CONTROL 4 A 5 n/a n/a no 
CONTROL 5 A 6 n/a n/a no 
CONTROL 6 A 7 n/a n/a no 
CONTROL 7 A 8 n/a n/a no 
CONTROL 8 A 8 n/a n/a no 
CONTROL 9 A 8 n/a n/a no 
CONTROL 10 A 8 n/a n/a no 
CONTROL 11 A 8 n/a n/a no 
CONTROL 12 A 9 n/a n/a no 
CONTROL 13 A 9 n/a n/a no 
CONTROL 14 A 9 n/a n/a no 
CONTROL 15 A 9 n/a n/a no 
CONTROL 16 A 11 n/a n/a no 
CONTROL 17 A 12 n/a n/a no 
CONTROL 18 A 13 n/a n/a no 
CONTROL 19 A 15 n/a n/a no 
CONTROL 20 A 18 n/a n/a no 
DMD1 A 5 Prednisolone Intermittent Deletion exons 49-52 
DMD2 A 5 Prednisolone Daily Deletion exon 51 
DMD3 A 5 No n/a Deletion exons 46-48 
DMD4 A 5 Prednisolone Intermittent Deletion exons 48-50 
DMD5 A 5 Prednisolone Every other day Deletion exons 48-52 
DMD6 A 6 Prednisolone Every other day Deletion exons 45-52 
DMD7 A 6 Prednisolone Intermittent Deletion exons 49-50 
DMD8 A 6 Prednisolone Daily Deletion exons 52-54 
DMD9 A 6 Prednisolone Intermittent Deletion exons 14-43 
DMD10 A 7 Prednisolone Intermittent Deletion exon 45 
DMD11 A 7 Prednisolone Daily Deletion exons 48-50 
DMD12 A 7 Deflazacort Daily Deletion exons 45-52 
DMD13 A 7 Prednisolone Daily Deletion exons 46,47,48,49 
DMD14 A 8 Prednisolone Intermittent Deletion exons 45-54 
DMD15 A 8 Prednisolone Intermittent Deletion exons 49-50 
DMD16 A 8 Prednisolone Intermittent Deletion exons 42-43 
DMD17 A 8 Prednisolone Daily Deletion exon 51 
or 
DMD18 A 8 Prednisolone Daily Deletion exon 45 
DMD19 A 8 Prednisolone Daily Deletion exons 53-54 
DMD20 A 8 Prednisolone Daily Deletion exons 45-52 
DMD21 A 8 Prednisolone Daily Deletion exon 43 
DMD22 A 9 Prednisolone Intermittent Deletion exons 54-52 
DMD23* A 9 Prednisolone Daily Deletion exons 51-54 
DMD24 A 9 Prednisolone Daily Deletion exon 51 
DMD25 A 10 Deflazacort Daily Deletion exons 45-52 
DMD26 A 10 Deflazacort Daily Deletion exons 45-52 
DMD27 A 10 Prednisolone Intermittent Deletion exons 42-43 
DMD28 A 11 Prednisolone Daily Deletion exons 49-50 
DMD29 A 11 Prednisolone Intermittent Stop mutation exon 19 
DMD30 A 12 Prednisolone Intermittent Deletion exon 44 
DMD31 A 14 Prednisolone Intermittent Duplication exons 49-50 
DMD32 A 14 Prednisolone Daily Deletion exons 48-54 
DMD33 NA 10 Prednisone Daily Deletion exons 45-50 
DMD34 NA 11 Prednisone Daily Deletion exons 45-50 
DMD35 NA 11 Prednisolone Every other day Deletion exon 50 
DMD36 NA 12 Prednisone Daily Deletion of exons 30-50 
DMD37 NA 12 No n/a Deletion exons 46-48 
DMD38 NA 12 No n/a Deletion exon 46 
DMD39 NA 12 No n/a Deletion exons 46-52 
DMD40 NA 12 Deflazacort Intermittent Deletion exons 46-49 
DMD41 NA 13 Prednisolone Intermittent Deletion exons 48-50 
DMD42 NA 13 Deflazacort Intermittent Deletion exon 53 
DMD43 NA 13 Deflazacort Intermittent Point mutation exon 44 
DMD44* NA 13 Deflazacort Daily Deletion exons 48-50 
DMD45 NA 14 Prednisolone Intermittent Deletion exon 45 
DMD46 NA 15 Prednisolone Intermittent Deletion exon 44 
DMD47 NA 15 Prednisolone Intermittent Deletion exons 46-51 
DMD48 NA 15 No n/a Deletion exons 46-55 
DMD49 NA 15 Prednisone Daily Deletion exons 45 
DMD50 NA 15 Prednisolone Intermittent Deletion exons 48-52 
DMD51 NA 16 Prednisolone Intermittent Deletion exon 51 
DMD52 NA 16 No n/a Deletion exon 52 
DMD53 NA 17 Deflazacort Daily Deletion exons 49-52 
DMD54 NA 18 Prednisone Daily Deletion exons 45-52 
DMD55 NA 18 No n/a Deletion exons 48-52 
DMD56 NA 19 Prednisone Daily Deletion exon 53 
A=ambulant patients, NA= non-ambulant patients, Intermittent =administered every 10 days, n/a= not 
applicable, * samples used only for profiling 
For 
Rev 
w 
Onl 
 
S2 Table. Exosomal microRNAs  tested. 
 
 
miRNA Target sequence  miRNA Target sequence 
hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU hsa-miR-106a-5p AAAAGUGCUUACAGUGCAGGUAG 
hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU hsa-miR-106b-5p UAAAGUGCUGACAGUGCAGAU 
hsa-let-7d-3p CUAUACGACCUGCUGCCUUUCU hsa-miR-107 AGCAGCAUUGUACAGGGCUAUCA 
hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA 
hsa-let-7e-5p UGAGGUAGGAGGUUGUAUAGUU hsa-miR-126-3p UCGUACCGUGAGUAAUAAUGCG 
hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU hsa-miR-128-3p UCACAGUGAACCGGUCUCUUU 
hsa-let-7g-5p UGAGGUAGUAGUUUGUACAGUU hsa-miR-133a-3p UUUGGUCCCCUUCAACCAGCUG 
hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU hsa-miR-135b-5p UAUGGCUUUUCAUUCCUAUGUGA 
hsa-miR-10a-5p UACCCUGUAGAUCCGAAUUUGUG hsa-miR-141-3p UAACACUGUCUGGUAAAGAUGG 
hsa miR 10b 5p UACCCUGUAGAACCGAAUUUGUG hsa miR 145 5p GUCCAGUUUUCCCAGGAAUCCCU 
hsa-miR-15a-5p UAGCAGCACAUAAUGGUUUGUG hsa-miR-148a-3p UCAGUGCACUACAGAACUUUGU 
hsa-miR-15b-5p UAGCAGCACAUCAUGGUUUACA  hsa-miR-148b-3p UCAGUGCAUCACAGAACUUUGU 
hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG hsa-miR-149-5p UCUGGCUCCGUGUCUUCACUCCC 
hsa-miR-17-5p CAAAGUGCUUACAGUGCAGGUAG  hsa-miR-151a-5p UCGAGGAGCUCACAGUCUAGU 
hsa-miR-20a-5p UAAAGUGCUUAUAGUGCAGGUAG  hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU 
hsa-miR-21-5p* UAGCUUAUCAGACUGAUGUUGA hsa-miR-187-3p UCGUGUCUUGUGUUGCAGCCGG 
hsa-miR-22-3p* AAGCUGCCAGUUGAAGAACUGU  hsa-miR-191-5p CAACGGAAUCCCAAAAGCAGCUG 
hsa-miR-22-5p AGUUCUUCAGUGGCAAGCUUUA  hsa-miR-193b-3p AACUGGCCCUCAAAGUCCCGCU 
hsa-miR-23a-3p AUCACAUUGCCAGGGAUUUCC  hsa-miR-195-5p UAGCAGCACAGAAAUAUUGGC 
hsa-miR-23b-3p* AUCACAUUGCCAGGGAUUACC hsa-miR-197-3p UUCACCACCUUCUCCACCCAGC 
hsa-miR-24-3p UGGCUCAGUUCAGCAGGAACAG hsa-miR-200a-3p UAACACUGUCUGGUAACGAUGU 
hsa-miR-25-3p CAUUGCACUUGUCUCGGUCUGA hsa-miR-200b-3p UAAUACUGCCUGGUAAUGAUGA 
hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU hsa-miR-200c-3p UAAUACUGCCGGGUAAUGAUGGA 
hsa-miR-26b-5p UUCAAGUAAUUCAGGAUAGGU hsa-miR-203a GUGAAAUGUUUAGGACCACUAG 
hsa-miR-27a-3p UUCACAGUGGCUAAGUUCCGC hsa-miR-204-5p UUCCCUUUGUCAUCCUAUGCCU 
hsa-miR-27b-3p UUCACAGUGGCUAAGUUCUGC hsa-miR-210-3p CUGUGCGUGUGACAGCGGCUGA 
hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC 
hsa-miR-29b-3p UAGCACCAUUUGAAAUCAGUGUU hsa-miR-222-3p AGCUACAUCUGGCUACUGGGU 
hsa-miR-29c-3p* UAGCACCAUUUGAAAUCGGUUA hsa-miR-301a-3p CAGUGCAAUAGUAUUGUCAAAGC 
hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG hsa-miR-342-3p UCUCACACAGAAAUCGCACCCGU 
hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU hsa-miR-365a-3p UAAUGCCCCUAAAAAUCCUUAU 
hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC hsa-miR-375 UUUGUUCGUUCGGCUCGCGUGA 
hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG hsa-miR-378a-3p ACUGGACUUGGAGUCAGAAGGC 
hsa-miR-30e-3p CUUUCAGUCGGAUGUUUACAGC hsa-miR-423-3p AGCUCGGUCUGAGGCCCCUCAGU 
hsa-miR-30e-5p UGUAAACAUCCUUGACUGGAAG hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU 
hsa-miR-31-3p UGCUAUGCCAACAUAUUGCCAU hsa-miR-425-5p AAUGACACGAUCACUCCCGUUGA 
hsa-miR-31-5p AGGCAAGAUGCUGGCAUAGCU hsa-miR-429 UAAUACUGUCUGGUAAAACCGU 
hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGU hsa-miR-500a-5p UAAUCCUUGCUACCUGGGUGAGA 
hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU hsa-miR-532-5p CAUGCCUUGAGUGUAGGACCGU 
hsa-miR-574-3p CACGCUCAUGCACACACCCACA 
hsa-miR-582-5p UUACAGUUGUUCAACCAGUUACU 
hsa-miR-598-3p UACGUCAUCGUUGUCAUCGUCA 
hsa-miR-660-5p UACCCAUUGCAUAUCGGAGUUG 
* Validated miRNAs 
hsa-miR-93-5p CAAAGUGCUGUUCGUGCAGGUAG 
hsa-miR-99a-5p AACCCGUAGAUCCGAUCUUGUG 
hsa-miR-99b-5p CACCCGUAGAACCGACCUUGCG 
hsa-miR-101-3p UACAGUACUGUGAUAACUGAA 
hsa-miR-103a-3p* AGCAGCAUUGUACAGGGCUAUGA 
 
S3 Table. Predicted target genes of the candidate   microRNAs. 
 
 
microRNA Predicted target genes from DIANA miRPath 
 
p-value 
 
KEGG pathway 
 
 
 
 
 
 
 
 
 
hsa-miR-21-5p 
ITGB8, THBS1, COL5A2, CD47 1.05E-11 ECM-receptor  interaction 
ERBB2, ITGB8, THBS1, BCL2, 
EGFR, PTK2, PIK3R1, 
PDGFD, VEGFA, PTEN, 
COL5A2 
 
2.12E-06 
 
Focal adhesion 
ERBB2, EGFR, PTK2, MYC, 
PIK3R1 2.31E-06 ErbB signaling pathway 
TGFBR1, ZFYVE16, MYC, 
TGFB2, TGFBR2, BMPR2 8.30355E-05 
TGF-beta signaling 
pathway 
TSC1, PIK3R1, RPS6KA3, 
VEGFA, PTEN, RRAGC 0.000527381 mTOR signaling pathway 
BID, BCL2, APAFI, PIK3R1, 
FAS 0.007398499 Apoptosis 
TGFBR1, EGFR, MAP3K1, 
RASA1, RASGRP1, MYC, 
DUSP8, FAS, RPS6KA3, 
TGFB2, MAP3K2, RASGRP3, 
MKNK2, TGFBR2 
 
 
0.0173412 
 
 
MAPK signaling pathway 
 
 
hsa-miR-22-3p 
 
SP1, BMP7 8.30355E-05 
TGF-beta signaling 
pathway 
PRKACA 0.007398499 Apoptosis 
PRKACA 0.0173412 MAPK signaling pathway 
hsa-miR-23b-3p STAT5B 2.31E-06 ErbB signaling pathway 
 
 
 
 
 
 
hsa-miR-29c-3p 
COL3A1, COL4A2, COL1A1, 
COL1A2, LAMC1, Col6a2, 
COL4A1 
 
1.05E-11 
 
ECM-receptor  interaction 
BCL2, COL3A1, JUN, COL4A2, 
COL1A1, COL1A2, LAMC1, 
AKT3, Col6a2, VEGFA, 
COL4A1 
 
2.12E-06 
 
Focal adhesion 
AKT2, JUN,AKT3 2.31E-06 ErbB signaling pathway 
AK2, AKT3, VEGFA 0.000527381 mTOR signaling pathway 
BCL2, AK2, AK3 0.007398499 Apoptosis 
AKT2, JUN, AKT3 0.0173412 MAPK signaling pathway 
 
 
 
 
hsa-miR-103a-3p 
ITGA2 1.05E-11 ECM-receptor  interaction 
BCL2, ZYX, ITGA2 2.12E-06 Focal adhesion 
ABL2, RPS6KB1 2.31E-06 ErbB signaling pathway 
 
ACVR2B, SMAD7, RPS6KB1 8.30355E-05 
TGF-beta signaling 
pathway 
RPS6KB1 0.000527381 mTOR signaling pathway 
FGF2, MAP3K7 0.007398499 Apoptosis 
FGF2, MAP3K7 0.0173412 MAPK signaling pathway 
 
